Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity

Frontiers in Molecular Biosciences, Journal Year: 2023, Volume and Issue: 10

Published: Aug. 3, 2023

Doxorubicin (DOX) is an extensively used chemotherapeutic agent that can cause severe and frequent cardiotoxicity, which limits its clinical application. Although there have been extensive researches on the cardiotoxicity caused by DOX, still a lack of effective treatment. It necessary to understand molecular mechanism DOX-induced search for new therapeutic targets do not sacrifice their anticancer effects. Mitochondria are considered be main target DOX. The imbalance mitochondrial dynamics characterized increased fission inhibited fusion often reported in result excessive ROS production, energy metabolism disorders, cell apoptosis, various other problems. Also, disorder related tumorigenesis. Surprisingly, recent studies show targeting proteins such as DRP1 MFN2 only defend against but also enhance or impair effect. Herein, we summarize cardiac injury. Furthermore, provide overview current pharmacological non-pharmacological interventions involved alleviate damage

Language: Английский

---

Mitochondrial Dysfunction in Cardiac Diseases and Therapeutic Strategies

Biomedicines, Journal Year: 2023, Volume and Issue: 11(5), P. 1500 - 1500

Published: May 22, 2023

Mitochondria are the main site of intracellular synthesis ATP, which provides energy for various physiological activities cell. Cardiomyocytes have a high density mitochondria and mitochondrial damage is present in variety cardiovascular diseases. In this paper, we describe cardiomyopathy, congenital heart disease, coronary myocardial ischemia-reperfusion injury, failure, drug-induced cardiotoxicity, context key roles cardiac development homeostasis. Finally, discuss current therapeutic strategies aimed at alleviating impairment-related dysfunction, including pharmacological strategies, gene therapy, replacement transplantation. It hoped that will provide new ideas treatment

Language: Английский

---

A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy

Small, Journal Year: 2024, Volume and Issue: 20(30)

Published: March 3, 2024

Abstract Doxorubicin (DOX) is widely used as a chemotherapeutic agent for both hematologic and solid tumors reasonable candidate glioma treatment. However, its effectiveness hindered by significant toxicity drug resistance. Moreover, the presence of blood–brain barrier (BBB) brings crucial challenge to therapy. In response, GSH‐responsive actively targeted nanoprodrug delivery system (cRGD/PSDOX‐Cur@NPs) are developed. this system, disulfide bond‐bridged DOX prodrug (PEG‐SS‐DOX) designed release specifically in high glutathione (GSH) tumor environment, markedly reducing cardiotoxicity associated with DOX. To further address resistance, curcumin, serving P‐glycoprotein (P‐gp) inhibitor, effectively increased cellular concentration. Consequently, cRGD/PSDOX‐Cur@NPs exhibited synergistic anti‐tumor effects vitro. Furthermore, vivo experiments validated superior BBB penetration brain‐targeting abilities cRGD/PSDOX‐Cur@NPs, showcasing remarkable potential treating subcutaneous orthotopic gliomas. This research underscores that presents novel approach inhibiting while addressing resistance systemic toxicity.

Language: Английский

---

Tetrastigma hemsleyanum polysaccharide combined with doxorubicin promote ferroptosis and immune function in triple-negative breast cancer

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 275, P. 133424 - 133424

Published: June 28, 2024

Language: Английский

---

MG53 inhibits ferroptosis by targeting the p53/SLC7A11/GPX4 pathway to alleviate doxorubicin-induced cardiotoxicity

Free Radical Biology and Medicine, Journal Year: 2024, Volume and Issue: 223, P. 224 - 236

Published: Aug. 6, 2024

Language: Английский

---